Celldex Therapeutics Inc. (CLDX)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, consistent earnings, and a margin of safety. Celldex fails most of those tests today. It is a clinical-stage biopharmaceutical company with 198 employees, developing antibody therapies for inflammatory, allergic, and autoimmune diseases. The financial statements show almost no commercial traction: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $22,000 and net loss was $73.5 million. For fiscal year 2025, revenue was $1.5 million and net loss was $258.8 million, worse than the $157.9 million loss in fiscal year 2024 and $141.4 million loss in fiscal year 2023. Revenue fell from $7.0 million in fiscal year 2024 to $1.5 million in fiscal year 2025. Free cash flow was negative $242.1 million over the trailing twelve months, a negative 10.9% FCF yield per FairStock. The balance sheet has little debt—debt-to-equity 0.01—and Altman Z-score 16.80 suggests low near-term insolvency risk, but cash burn is heavy. Piotroski F-score is 3/9, ROE is -43.88%, and at the 2026-10-13 close the stock trades at P/B 3.10 with no meaningful P/E because the company is loss-making; fiscal year 2025 diluted EPS was -$3.90. The Lynch category is none: losses in each of the last three years. A moat could emerge from the mast-cell antibody pipeline, but there is no financial proof yet. Without earnings, predictable cash flows, or a verifiable discounted asset value, I see speculation, not a Graham-style bargain. The FairStock Score of 23/100 confirms weak fundamentals.

In plain English: Celldex Therapeutics is a small biotech company trying to develop antibody medicines for serious inflammatory and allergic diseases. It earns almost no revenue and loses large amounts of money, with losses growing and cash going out the door. At $28.25, the shares are hard to call cheap because there are no profits, and the company looks financially weak today.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer